GAITHERSBURG, Md.--(BUSINESS WIRE)--Ore Pharmaceuticals Inc. (NASDAQ:ORXE) announced today that, at its annual meeting, its stockholders approved a proposed one-for-five reverse stock split of the Company’s common stock, re-elected directors J. Stark Thompson, Ph.D. and Mark Gessler to terms expiring in 2011, and ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2008.
